Guardian Pharmacy Services (NYSE:GRDN) Announces Earnings Results

Key Points

• Guardian Pharmacy Services reported quarterly EPS of $0.33, beating the $0.31 consensus, and revenue of $371.1 million, above expectations of $365.8 million.
• The company raised its 2026 guidance to $1.44 billion–$1.46 billion in revenue and $136 million–$138 million in Adjusted EBITDA; third-quarter Adjusted EBITDA grew 24% year over year to $33.9 million.
• Revenue declined 1.7%, mainly because of IRA-related drug price reductions, though prescription volume rose 10%. Management said revenue would have grown at a high-single-digit rate without the price impact.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.02, FiscalAI reports. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%. The business had revenue of $371.07 million during the quarter, compared to analysts' expectations of $365.76 million.

Here are the key takeaways from Guardian Pharmacy Services' conference call:

• Guardian raised 2026 guidance to revenue of $1.44 billion–$1.46 billion and Adjusted EBITDA of $136 million–$138 million. Third-quarter Adjusted EBITDA rose 24% year over year to $33.9 million, while net income nearly doubled to $19 million.
• Reported revenue fell 1.7% to $371 million, primarily due to IRA-related drug price reductions; management said revenue would have grown at a high-single-digit rate without that impact. Prescription volume increased 10% year over year.
• Growth efforts include new pharmacy locations and acquisitions, including Nautilus, whose residents were transitioned to Guardian pharmacies and whose deal is expected to be accretive after onboarding costs. Management said its acquisition pipeline remains active and sees room to expand through both acquisitions and greenfield openings.
• Management cited improving assisted-living occupancy, complex resident care needs, and Guardian’s estimated 14% share of its primary market as support for continued growth. It said service quality and facility wins—not occupancy alone—are central to expanding the business.
• Guardian is working with payers on reimbursement that better reflects its services and generic-drug mix, which management believes could improve the business’s long-term stability. The company ended the quarter with about $120 million in cash and no debt.

Guardian Pharmacy Services Price Performance

Shares of Guardian Pharmacy Services stock traded up $2.58 during trading on Friday, hitting $42.45. 1,085,464 shares of the company's stock traded hands, compared to its average volume of 383,960. The company has a market cap of $2.11 billion, a PE ratio of 36.28, a PEG ratio of 2.09 and a beta of 0.06. The firm's fifty day moving average price is $41.42 and its 200 day moving average price is $38.30. Guardian Pharmacy Services has a twelve month low of $26.34 and a twelve month high of $48.33.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GRDN. Wall Street Zen cut shares of Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a research note on Sunday, October 25th. KeyCorp assumed coverage on Guardian Pharmacy Services in a research report on Tuesday, September 22nd. They set an "overweight" rating and a $52.00 target price on the stock. Truist Financial upped their price target on Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a "buy" rating in a report on Monday, September 21st. Oppenheimer raised their price objective on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an "outperform" rating in a research report on Friday, August 7th. Finally, Weiss Ratings lowered Guardian Pharmacy Services from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, October 23rd. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Guardian Pharmacy Services currently has a consensus rating of "Moderate Buy" and an average target price of $45.57.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc is a provider of pharmacy services focused primarily on residents of long-term care and other institutional healthcare settings. Through its network of pharmacies, the company supplies prescription medications and related pharmacy support to assisted living communities, skilled nursing facilities, behavioral health organizations, and other care providers.

The company's services include medication dispensing and packaging, prescription delivery, medication management, clinical pharmacy support, and technology-enabled tools designed to help caregivers and healthcare professionals manage residents' medication regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.